Document Detail


The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia.
MedLine Citation:
PMID:  10163332     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To determine the impact of a 5-alpha-reductase inhibitor on the need for surgical treatment of symptomatic benign prostatic hyperplasia (BPH) in clinical urologic practice, we retrospectively reviewed records of 794 patients treated with pharmacotherapy or surgery (or both). The number of transurethral resections of the prostate (TURPs) performed during the 30 months since introduction of finasteride was compared with the number performed during the 30 months before finasteride became available. The alpha-blockers doxazosin and prazosin were used during both times for the treatment of BPH. Of the 619 patients treated with drugs, 88.5% received finasteride for a mean of 249.6 days. The alpha-blockers, either alone or combined with finasteride, were prescribed for 11.5% of patients for a mean of 179 days. In the 30 months after the introduction of finasteride, 65 patients underwent TURP: 28 of these men had initially received drug therapy. In contrast, 138 TURPs were performed in the 30 months prior to the availability of finasteride. The use of a 5-alpha-reductase inhibitor as primary medical therapy for symptomatic BPH decreased the number of prostatectomies by 52.9% (65 vs 138). This observation warrants corroboration through additional prospective studies.
Authors:
A H Agha; J B Roy; D J Culkin; K Lyon
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Advances in therapy     Volume:  12     ISSN:  0741-238X     ISO Abbreviation:  Adv Ther     Publication Date:    1995 Nov-Dec
Date Detail:
Created Date:  1996-11-06     Completed Date:  1996-11-06     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8611864     Medline TA:  Adv Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  361-6     Citation Subset:  T    
Affiliation:
Department of Urology, University of Oklahoma College of Medicine, Oklahoma City, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic alpha-Antagonists / therapeutic use
Aged
Doxazosin / therapeutic use
Enzyme Inhibitors / therapeutic use*
Finasteride / therapeutic use*
Humans
Male
Prazosin / therapeutic use
Prostatectomy / statistics & numerical data*
Prostatic Hyperplasia / drug therapy*,  surgery*
Retrospective Studies
Treatment Outcome
Chemical
Reg. No./Substance:
0/Adrenergic alpha-Antagonists; 0/Enzyme Inhibitors; 19216-56-9/Prazosin; 74191-85-8/Doxazosin; 98319-26-7/Finasteride

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Maintenance treatment in the prevention of gastric ulcer recurrence: results of a 3-year multicenter...
Next Document:  Bileaflet valve replacement: complications and costs.